Active Biotech AB Interim report January - March 2012

(Thomson Reuters ONE) -


* Laquinimod - submission of application for regulatory approval in the EU
planned for second half of 2012
                 - Phase III data presented at the Annual Meeting of the
American Academy of Neurology (AAN)
* TASQ        - a Phase I investigator-sponsored clinical trial is under way
                 - enrolment of patients to Phase III study proceeding
according to schedule
* ANYARA     - Phase III trial continuing according to plan
* 57-57          - a clinical trial in systemic sclerosis/scleroderma in
progress
* ISI               - project is proceeding as planned
* Net sales SEK 2.6 M (2.7)
* Operating loss SEK 100.7 M (loss: 70.9)
* Net loss SEK 99.0 M (loss: 69.3 )
* Loss per share for the period was SEK 1.44 (loss: 1.02)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44


Active Biotech AB (Corp Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com




Active Biotech AB Interim report January - March 2012:
http://hugin.info/1002/R/1605995/508858.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE
[HUG#1605995]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 26.04.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 139463
Anzahl Zeichen: 1989

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 142 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - March 2012"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech